Exicure has concluded subject enrolment in its ongoing randomised Phase II trial on GPC-100 (burixafor) in conjunction with ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.84%, which has investors questioning if this is right time to buy.

an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication ...

Nektar Therapeutics’s NKTR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.

Achieved $20.0 million in Revuforj net revenue in the first quarter of 2025, the first full quarter of the U.S. launch. Revuforj was launched in the U.S. in late November 2024 for the treatment of ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash ...